Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 1/20 | 0.57 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.48 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.40 |
| ▸ | ALPG | P10696 | 1/20 | 0.40 |
| ▸ | SLC34A1 | Q06495 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2891690 | 0.89 | BCL6 (0.57) | BCL6KCNN2KCNN3TP53MAPT | |
| SCHEMBL2886270 | 0.88 | BCL6 (0.56) | BCL6KCNN2KCNN3TP53MAPT | |
| SCHEMBL2885801 | 0.87 | BCL6 (0.55) | BCL6KCNN2KCNN3TP53MAPT | |
| SCHEMBL2889626 | 0.87 | BCL6 (0.55) | BCL6KCNN2KCNN3TP53MAPT | |
| SCHEMBL2891047 | 0.84 | BCL6 (0.52) | BCL6KCNN2KCNN3TP53MAPT | |
| SCHEMBL2889620 | 0.80 | BCL6 (0.57) | BCL6KCNN2KCNN3TP53MAPT | |
| SCHEMBL2885622 | 0.80 | BCL6 (0.51) | BCL6KCNN2KCNN3TP53MAPT | |
| SCHEMBL2891269 | 0.77 | BCL6 (0.54) | BCL6KCNN2KCNN3TP53MAPT | |
| SCHEMBL2891272 | 0.77 | BCL6 (0.54) | BCL6KCNN2KCNN3TP53MAPT | |
| SCHEMBL2891529 | 0.76 | BCL6 (0.53) | BCL6KCNN2KCNN3TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415358-B2 | Pyrazine derivatives and their use as potassium channel modulators | NEUROSEARCH A/S (DK) | 2013-04-09 | — | — | US | claimed |
| US-20100286161-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2010-11-11 | — | — | US | claimed |
| EP-2203436-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-07-07 | — | — | EP | claimed |
| WO-2009037247-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2009-03-26 | — | — | WO | claimed |
| US-8415358-B2 | Pyrazine derivatives and their use as potassium channel modulators | NEUROSEARCH A/S (DK) | 2013-04-09 | — | — | US | disclosed |
| US-8415358-B2 | Pyrazine derivatives and their use as potassium channel modulators | NEUROSEARCH A/S (DK) | 2013-04-09 | — | — | US | disclosed |
| US-8415358-B2 | Pyrazine derivatives and their use as potassium channel modulators | NEUROSEARCH A/S (DK) | 2013-04-09 | — | — | US | disclosed |
| US-20100286161-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100286161-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100286161-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2010-11-11 | — | — | US | disclosed |
| EP-2203436-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009037247-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286161-A1 | PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNQ5, KCNA5 | BCL6 3342/4885KCNN2 32/4885KCNN3 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.